ClinConnect ClinConnect Logo
Search / Trial NCT01061203

Grazax Asthma Prevention

Launched by ALK-ABELLÓ A/S · Feb 1, 2010

Trial Information

Current as of June 01, 2025

Completed

Keywords

Rhinitis Allergic Seasonal Grass Asthma

ClinConnect Summary

Investigation of the effect of Grazax (ALK produced grass tablet) on asthma prevention in children with grass pollen allergy.

Children in the age of 6-12 years will be randomised to either placebo or Grazax treatment. Grazax has been approved for treatment of grass pollen allergy in adults and children, diagnosed with a positive skin prick test and/or specific immunoglobulin (IgE) test to grass pollen and with clinically relevant symptoms. This study will explore prevention of asthma in children with grass pollen induced allergy.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • A history of grass pollen allergy
  • Positive Skin prick test to grass
  • Positive specific IgE to grass
  • Exclusion Criteria:
  • Asthma

About Alk Abelló A/S

ALK-Abelló A/S is a global biopharmaceutical company specializing in the development of innovative allergy immunotherapy treatments. With a strong commitment to improving patient outcomes, ALK focuses on research and development of products that address various allergic conditions, including asthma, rhinitis, and food allergies. Leveraging advanced scientific expertise and a robust pipeline of therapies, ALK aims to enhance the quality of life for individuals affected by allergies while adhering to the highest standards of safety and efficacy in clinical trial practices. The company is dedicated to advancing the field of allergy treatment through collaboration and innovation.

Locations

Turku, , Finland

Patients applied

0 patients applied

Trial Officials

Erkka Valovirta, MD

Principal Investigator

Terveystalo Turku, Finland

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials